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Background / Aims: Elevated oxidative status has been found in many types of cancer 
cells. Recent studies have shown that the enzymatic product of thymidine 
phosphorylase (TP) generated reactive oxygen species (ROS) within cancer cells. The 
aim of this study was thus to evaluate the signal transduction pathway and the role of 
ROS in colorectal cancer. Methodology: Blood specimens were obtained from the 
drainage vein of the tumor during operation in 76 patients with colorectal cancer. Serum 
ROS levels were measured using the derivative-Reactive Oxygen Metabolites (d-ROM) 
test and serum TP levels were examined by a highly sensitive ELISA method. Results: 
There was no significant correlation between serum levels of ROS and TP. Serum ROS 
levels were elevated in proportion to tumor invasion and had a significant positive 
correlation with tumor size (p<0.05). However, they did not increase in patients with 
liver metastasis. Conclusions: These findings suggest that ROS are independent of 
TP-triggered signaling transduction and are associated with increased tumor invasion, 
but not liver metastasis in patients with colorectal cancer. From this point of view, new 
strategies related to ROS may provide improved therapeutic results as well as a 





Reactive oxygen species (ROS) include superoxide radical anion (O2
-), hydroxyl radical 
(・OH), and hydrogen peroxide (H2O2) and play important roles in cell growth and 
intracellular signal transduction pathways (1-5). Excessive production of intracellular 
ROS has been reported to result in an oxidative environment which damages cellular 
molecules or modulates gene expression (6-8).  
The colon is constantly exposed to ROS originating from endogenous and exogenous 
sources (9). It is well known that enhanced oxidative stress of the colon is associated 
with an increased risk of cancer (10-12). In addition, ROS have been proposed to be 
involved in tumor metastasis, which is a complicated processes including 
epithelial-mesenchymal transition (EMT), migration, invasion of the tumor cells and 
angiogenesis (13, 14). A more comprehensive understanding of ROS-triggered signaling 
transduction, transcriptional activation and regulation of gene expression will help 
strengthen our understanding of the critical role of ROS in tumor progression. 
Recent studies have reported that the enzymatic product of thymidine phosphorylase 
(TP), an enzyme involved in pyrimidine metabolism, generates ROS within a 
TP-overexpressing cancer cell and free radical stress increases tumor cell production of 
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angiogenic factors and an intestinal collagenase (14-16). In our previous studies, we 
showed that the serum TP levels in venous blood drainage specimens reflect the 
prognosis of patients with colorectal cancer, particularly the risk of liver metastasis (17, 
18). However, it remains unclear why the serum TP levels are elevated in patients with 
liver metastasis. Accordingly, the purpose of the present study was to investigate 
whether an oxidative stress mechanism is regulated by TP and to evaluate the role of 




Patients and Tumor Samples 
 Seventy-six patients (47 males and 29 females) with colorectal cancer, who underwent 
surgery between June 1997 and January 2002 in the Department of Surgery, Nagasaki 
University, were enrolled as subjects (Table 1). None had received chemotherapy or 
irradiation prior to surgery. Twelve patients had liver metastases (10 patients with 
synchronous metastasis and 2 patients with metachronous metastasis). The average age 
at surgery was 65.3 years (range, 34-87 years). The average follow-up period was 89.4 
months. The extent of tumor invasion was based on TNM classification. Five patients 
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were classified as T1, 7 as T2, 55 as T3, and 9 as T4. Thirty-three patients had lymph 
node metastases. Serum samples were collected after obtaining informed consent from 
each patient in accordance with institutional guidelines. All patients had histologically 
verified adenocarcinoma of the colon or rectum. 
 
Clinical Follow-Up 
 All patients were followed up after discharge by physical examination, routine serum 
chemistries and serum tumor marker tests every 1-3 months and by abdominal 
ultrasonography and computed tomography every 3-6 months. 
 
Measurement of the Serum TP Levels 
 The serum samples were obtained from venous blood drainage specimens of the 
primary tumor immediately after laparotomy, and then were stored at -80ºC until use. 
The serum TP levels were determined by enzyme-linked immunosorbent assay (ELISA) 
using the previously reported method with the following modifications (17, 18). The 
same pair of monoclonal antibodies - 104B and 232-2 - was used, but 232-2 was labeled 
with biotin and its binding was detected by peroxidase-conjugated streptavidin. Due to 
these modifications, the accuracy of the ELISA was improved 25-fold in comparison to 
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the original procedure. In serum from the peripheral blood of 16 healthy volunteers, the 
mean TP level was 14.1±5.2ng/ml. 
 
Measurement of the Serum d-ROM Levels 
The oxidative status was studied by measuring hydroperoxides in the serum using the 
d-ROM (derivatives of reactive oxygen metabolites) test. The test was carried out using 
the Free Radical Analytical System 4 (FRAS4; Wismerll Co. Ltd. Tokyo, Japan). The 
test is based on the concept that the amount of organic hydroperoxides present in serum 
is related to the free radicals from which they are formed. When the serum sample is 
dissolved in an acidic buffer, the hydroperoxides react with the transition metal ions 
liberated from the proteins in the acidic medium and are converted to alkoxy and peroxy 
radicals. These newly formed radicals are able to oxidize an additive (N, 
N-diethyl-para-phenylendiamine) to the corresponding radical cation. It was reported 
that the value of serum ROS had a high positive correlation with the serum d-ROM 
value of measured by the d-ROM test (19-21). The concentration of this persistent 
species can be easily determined through spectrophotometric procedures (absorption at 
505 nm), and are generally expressed in conventional units (Carratelli units; U.CARR), 
in which 1U.CARR corresponds to 0.8mg/lH2O2. The normal values of the test are less 
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than 300U.CARR. Values>300U.CARR indicate a condition of oxidative stress 
(301-320U.CARR: borderline, 321-340U.CARR: mild oxidative stress, 
341-400U.CARR: moderate oxidative stress, 401-500U.CARR: strong oxidative stress, 
501U.CARR and higher: very strong oxidative stress). 
 
Statistical Analyses 
 All data were expressed as the means±standard deviation. The Mann-Whitney test 
was used to determine statistically significant differences between two groups. 
Spearman’s correlation was used to examine correlations. Differences were considered 




Relationship between the serum levels of d-ROM and TP 
 The serum d-ROM and TP levels in venous blood drainage specimens were 
successfully measured in all patients in this study. The mean of the serum d-ROM levels 
was 317.4±68.6U.CARR, and the mean of the serum TP levels was 52.1±51.9ng/ml. 
As shown in Figure 1, the serum d-ROM levels were not significantly correlated with 
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the serum TP levels (p=0.77). 
 
Relationship between the serum d-ROM and TP levels and tumor growth 
First, the correlation between the serum d-ROM or TP levels and the clinicopathologic 
features was evaluated. A statistically significant correlation was observed between the 
serum d-ROM levels and tumor size (p=0.036). The serum d-ROM levels were 329.9±
77.1U.CARR in patients with a tumor of more than 40mm and 301.0±52.5U.CARR in 
patients with a tumor of less than 40mm (Figure 2A). No significant correlation was 
noted between the serum TP levels and tumor size (Figure 2B). 
The serum d-ROM levels of each depth of invasion group are shown in Figure 3A. 
The serum d-ROM levels were 291.4±78.8U.CARR in the T1 group, 305.1±
38.1U.CARR in the T2 group, 320.1±72.8U.CARR in the T3 group, and 324.9±
59.1U.CARR in the T4 group. As the tumor invasion progressed, there was a trend 
toward a greater increase in the serum d-ROM levels. On the other hand, there was no 
correlation between the serum TP levels and the depth of invasion (Figure 3B). None of 
the other variables, including age, gender, tumor site, and lymph node metastasis, 




Serum d-ROM and TP levels and liver metastasis 
 The serum d-ROM levels in the 12 patients with liver metastasis were not significantly 
correlated with those in the 64 patients without liver metastasis (326.1±73.5U.CARR 
vs. 315.8±68.2U.CARR) (Figure 4A). 
 On the other hand, the serum TP levels in the patients with liver metastasis were 
significantly higher than those in the patients without liver metastasis (111.6±
81.1ng/ml versus 40.9±35.5ng/ml: p<0.001) (Figure 4B). 
 
DISCUSSION 
We previously indicated that serum TP levels were significantly elevated in colorectal 
cancer patients with liver metastasis and reflected the prognosis (17, 18). TP, which is 
identical to platelet-derived endothelial cell growth factor, is an angiogenic factor and 
catalyzes the reversible phosphorolysis of thymidine, deoxyuridine and their analogs 
(22-24). However, it remains uncertain how TP associates with the cascade of liver 
metastasis in colorectal cancer. 
Recent studies have reported that 2-deoxy-D-ribose-1-phosphate (2dDR1P) released 
from thymidine by TP generates oxygen radicals, and that free radical oxidative stress 
causes angiogenesis and metastasis (14, 16). ROS can stimulate cell proliferation, 
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promote genetic instability, and induce adaptive responses that enable cancer cells to 
maintain their malignant phenotypes. ROS-mediated DNA damage has long been 
thought to play an important role in carcinogenesis initiation and malignant 
transformation by leading to mutations in tumor suppressor genes (25). The 
gastrointestinal tract, especially the colon, is constantly exposed to ROS originating 
from endogenous and exogenous sources, and ROS have been associated with an 
increased risk of colon cancer (14, 26). 
Therefore, we hypothesized that a TP-triggered signal transduction pathway plays a 
role in the liver metastasis of patients with colorectal cancer. The mechanism of this 
association would proceed as follows. (1)The downstream mediators of TP function 
give rise to oxidative stress. (2)ROS increase tumor cell production of the angiogenic 
factors interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF), in addition 
to inducing production of matrix metalloproteinase-1 (MMP-1). This gives rise to 
(3)liver metastasis of the colorectal cancer. 
 To examine this hypothesis, we measured serum ROS levels using the d-ROM test and 
compared them with serum TP levels. The results showed that there was no significant 
correlation between the serum levels of ROS and TP. In addition, serum ROS levels 
were not significantly elevated in colorectal cancer patients with liver metastasis. In 
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contrast, serum ROS levels were elevated in proportion to tumor invasion and had a 
significant positive correlation with tumor size. These results suggest that TP may be 
involved in liver metastasis by regulating another intracellular signal transduction, and 
that the mechanism of ROS-triggered signal transduction has relation to tumor invasion, 
but not tumor metastasis in colorectal cancer (Figure 5). In fact, with respect to factors 
other than TP, several previous reports have demonstrated that ROS generation may be 
induced intracellularly, in either an NADPH oxidase-dependent or a mitochondria- 
dependent manner, by growth factors and cytokines (TGFbeta1 and HGF) and tumor 
promoters (such as TPA) capable of triggering cell adhesion, EMT and migration (25, 
27, 28). 
   In conclusion, it may be possible to prevent tumor progression by regulating ROS, 
which enhance cell proliferation and apoptosis suppression. For example, one possible 
therapeutic strategy targeting ROS-triggered signal transduction would be to increase 
ROS scavenging, thereby dampening H2O2 signaling and depressing tumor growth. In 
general, clarification of the true role of ROS in various cancers will lead to new 
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Figure 1  Correlation between the serum thymidine phosphorylase (TP) levels and the 
serum derivatives of reactive oxygen metabolites (d-ROM) levels in venous blood 
drainage specimens from colorectal cancer patients. 
 
Figure 2  Relationship between the serum derivatives of reactive oxygen metabolites 
(d-ROM) levels (A) and the serum thymidine phosphorylase (TP) levels (B) and tumor 
size. Data points represent the means±standard deviation. NS, not significant. 
 
Figure 3  Relationship between the serum derivatives of reactive oxygen metabolites 
(d-ROM) levels (A) and the serum thymidine phosphorylase (TP) levels (B) and depth 
of invasion of colorectal cancer. Bars represent the standard deviation. 
 
Figure 4  Plot depicting the serum derivatives of reactive oxygen metabolites (d-ROM) 
levels (A) and the serum thymidine phosphorylase (TP) levels (B) according to presence 
or absence of liver metastasis. Points (○) are the observed serum d-ROM or TP levels 




Figure 5  Schematic representation of the roles of thymidine phosphorylase (TP) and 
reactive oxygen species (ROS) in tumorigenesis. 
Characteristics No. of patients %
Age (yr)
  Median 65.3
  Range 34-87
Gender
  Male 47 62
  Female 29 38
Tumor site
  Colon 41 54
  Rectum 35 46
Depth of invasion
  T1 5 7
  T2 7 9
  T3 55 72
  T4 9 12
Tumor size
  ≤ 40 mm 33 43
  > 40 mm 43 57
Lymph nodes metastasis
  (－) 43 57
  (＋) 33 43
Liver metastasis
  (－) 64 84
  (＋) 12 16
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